Corcept Therapeutics Incorporated  

(Public, NASDAQ:CORT)   Watch this stock  
Find more results for cort
6.49
0.00 (0.00%)
Sep 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.36 - 6.56
52 week 3.22 - 6.60
Open 6.48
Vol / Avg. 0.00/272,562.00
Mkt cap 717.76M
P/E 562.39
Div/yield     -
EPS 0.01
Shares 110.59M
Beta 1.23
Inst. own 55%
Nov 29, 2016
Corcept Therapeutics Inc at Piper Jaffray Healthcare Conference Add to calendar
Nov 3, 2016
Q3 2016 Corcept Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Oct 5, 2016
Corcept Therapeutics Inc at Cowen Therapeutics Conference Add to calendar
Sep 12, 2016
Corcept Therapeutics Inc at Morgan Stanley Global Healthcare Conference
Aug 2, 2016
Q2 2016 Corcept Therapeutics Inc Earnings Call
Aug 2, 2016
Q2 2016 Corcept Therapeutics Inc Earnings Release
Jul 12, 2016
Corcept Therapeutics Inc at Cantor Fitzgerald Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 4.95% -12.74%
Operating margin 7.65% -6.85%
EBITD margin - -6.54%
Return on average assets 7.14% -14.81%
Return on average equity 17.10% -84.82%
Employees 78 -
CDP Score - -

Address

149 Commonwealth Drive
MENLO PARK, CA 94025
United States - Map
+1-650-3273270 (Phone)
+1-650-3273218 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company's focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). It has also discovered approximately three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor, and so do not terminate pregnancy or cause other side effects associated with progesterone receptor antagonism. It has begun pre-clinical and clinical development of its lead compounds from these series.

Officers and directors

James N. Wilson Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Joseph K. Belanoff M.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Gary Charles Robb Chief Financial Officer, Chief Accounting Officer, Secretary
Age: 52
Bio & Compensation  - Reuters
Renee D. Gala Director
Age: 44
Bio & Compensation  - Reuters
Len L. Baker Jr. Independent Director
Age: 62
Bio & Compensation  - Reuters
Daniel Mark Bradbury Independent Director
Age: 54
Bio & Compensation  - Reuters
Joseph C. Cook Jr. Independent Director
Age: 73
Bio & Compensation  - Reuters
Patrick G. Enright Independent Director
Age: 54
Bio & Compensation  - Reuters